Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:diabetes
|
| gptkbp:administered_by |
various forms
injection diabetic patients |
| gptkbp:available_on |
synthetic insulin
|
| gptkbp:developed_by |
pancreas
|
| gptkbp:discovered_by |
gptkb:Sir_Frederick_Banting
gptkb:Charles_Best |
| gptkbp:first_introduced |
gptkb:1922
|
| gptkbp:has_impact_on |
lowers blood sugar
|
| https://www.w3.org/2000/01/rdf-schema#label |
C. H. Best XL
|
| gptkbp:ingredients |
hyperglycemia
|
| gptkbp:is_a |
gptkb:Hirogen
|
| gptkbp:is_associated_with |
gptkb:Type_1_diabetes
Type 2 diabetes |
| gptkbp:is_considered |
life-saving medication
|
| gptkbp:is_essential_for |
metabolism of carbohydrates
|
| gptkbp:is_involved_in |
energy homeostasis
|
| gptkbp:is_linked_to |
metabolic syndrome
obesity |
| gptkbp:is_noted_for |
its effectiveness
its affordability its stability its long-term effects its impact on quality of life its availability its side effects its safety profile its short duration its rapid action its administration routes its contraindications its dosage forms its interactions with other medications its monitoring requirements its patient education requirements its role in diabetes advocacy its role in diabetes education its role in diabetes research its role in healthcare policy its role in public health initiatives its storage requirements |
| gptkbp:is_part_of |
endocrine system
insulin therapy |
| gptkbp:is_regulated_by |
glucose levels
|
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_used_in |
diabetes management
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:measures |
blood tests
|
| gptkbp:produced_by |
recombinant DNA technology
beta cells |
| gptkbp:regulates |
blood glucose levels
|
| gptkbp:used_for |
treatment of diabetes
|
| gptkbp:bfsParent |
gptkb:Caterpillar_Inc.
|
| gptkbp:bfsLayer |
4
|